{"DataElement":{"publicId":"5514976","version":"1","preferredName":"Person Gene Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for any questions related to the results of gain, loss or alteration of the sequences comprising a gene, including all sequences transcribed into RNA as outlined in the protocol.","longName":"GNMTN_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5514972","version":"1","preferredName":"Person Gene Mutation Clinical Trial Eligibility Criteria","preferredDefinition":"A human being._change occurring in one gene._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"5514970v1.0:2494487v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"5514970","version":"1","preferredName":"Person Gene Mutation","preferredDefinition":"A human being.:change occurring in one gene.","longName":"C25190:C18093","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gene Mutation","conceptCode":"C18093","definition":"The result of any gain, loss or alteration of the sequences comprising a gene, including all sequences transcribed into RNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EC09928-DCF3-2B1A-E053-F662850A1238","latestVersionIndicator":"Yes","beginDate":"2016-10-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-13","modifiedBy":"ONEDATA","dateModified":"2016-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2494487","version":"1","preferredName":"Clinical Trial Eligibility Criteria","preferredDefinition":"Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17D7DFE2-3794-35DA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-07-05","modifiedBy":"ONEDATA","dateModified":"2006-07-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435027","version":"1","preferredName":"Gene","preferredDefinition":"A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule).","longName":"C16612","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB05-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EC09928-DD01-2B1A-E053-F662850A1238","latestVersionIndicator":"Yes","beginDate":"2016-10-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-13","modifiedBy":"TAYLORT","dateModified":"2016-10-19","changeDescription":"10/19/16 tt, released. 10/13/16 tt, 9767.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Does patient's TCCs tumor har","type":"Preferred Question Text","description":"Does patient's TCCs tumor harbor TSC1 or TSC2 mutation identified by a CLIA certified laboratory?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does patient have CLIA confirmed somatic KRAS G12R mutation as determined by sequence analysis of matched normal DNA from any specimen obtained from the individual?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient have a malignancy that contains a non-synonymous mutation, insertion, or deletion in the TP53 gene determined prior to screening?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Has the presence of biallelic loss of SETD2 been detected in tumor tissue using a CLIA-certified next generation sequencing panel (e.g. UCSF500, FoundationOne)?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does patient in Cohort A have the presence of biallelic loss of SETD2 been detected in tumor tissue using a CLIA-certified next generation sequencing panel (e.g. UCSF500, FoundationOne)?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Does patient have PTEN or PIK3CB mutated advanced solid tumor?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does patient in Cohort A have the presence of pathogenic SETD2 mutation detected in tumor tissue using a CLIA-certified next generation sequencing panel (e.g. UCSF500, FoundationOne)?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does patient in Cohort 2 have CLIA confirmed presence of a somatic or germline alteration in one or more of the DNA-repair genes tested in the FoundationOne®CDx (F1CDx)  panel including the following genes: ABL1, ATR, ATRX, BARD1, BLM, BRD4, CCND1, CHEK1, CHEK2, DOT1L, FANCC, FANCD2, FANCE, FANCG, FANCL, IKBKE, MEN1, MLH1, MSH2, MSH6, MUTYH, NPM1, PMS2, POLD1, POLE, PRKDC, RAD50, RAD51, SMARCB1, STK11?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Does patient have one of the following specific mutations that lead to a neomorphic phenotype and include the following: IDH1: R132V, R132G, R132S, R132L, R132C, and R132H. For IDH2: R140W, R140L,R140Q, R172W, R172G, R172S, R172M and R172K, will be eligible for enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If enrolled in the Phase 2, RP2D, does patient have the presence of an actionable mutation in either PIK3CA gene or PTEN gene performed at a CLIA certified laboratory?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has patient had tumor sequencing for evaluation of actionable PIK3CA or PTEN mutations performed in a CLIA certified, CAP tested and bioinformatics-validated testing lab PRIOR to enrollment in this current protocol or if patient has not yet had tumor genomic assessment, after consultation with the PI, tumor specimens will be sent to the UNC Hospitals Clinical Molecular Genetics Laboratory for assessment of the Solid Tumor Mutation Panel?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Does patient have germline or somatic mutations in DDR genes: ARID1A, ATM, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2, PARP1, POLD1, PP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, XRCC2; or actionable mutations in the PTEN gene, or hotspot mutations in the PIK3CA gene (E542, E545 or H1047 are accepted)?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does patient in Cohort 2 have CLIA testing and fit the group with the confirmed presence of a cancer-associated alteration in one or more of the DNA-repair genes tested in the FoundationOne panel including the following genes: ABL1, ATR, ATRX, BARD1, BRD4, CCND1, CHEK1, CHEK2, DOT1L, FANCC, FANCE, FANCG, FANCL, IKBKE, MEN1, MLH1, MSH2, MSH6, MUTYH, NPM1, PMS2, POLD1, POLE, RAD51, SMARCB1, STK11?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Does patient have known mutation status for PIK3CA and PTEN from archival tumor tissue analysis?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Does patient have PI3K pathway activating genomic alterations including inactivating mutations/deletions in PTEN and PIK3R1, amplifications in PIK3CA, and activating mutations in PIK3CA, Akt, or mTOR?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Does patient in Cohort 2 have CLIA testing and fit the group with the confirmed presence of a cancer-associated alteration in one or more of the DNA-repair genes tested in the FoundationOne panel including the following genes: ABL1, ATR, ATRX, BARD1, BRD4, CCND1, CHEK1, CHEK2, DOT1L, FANCC, FANCE, FANCG, FANCL, IKBKE, MEN1, MLH1, MSH2, MSH6, MUTYH, NPM1, PMS2, POLD1, POLE, RAD51, SMARCB1, STK11, TP53?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does patient have the presence of an actionable mutation in either PIK3CA or PTEN on molecular testing?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Does patient have germline or somatic mutations in DDR genes: BARD1, BRCA1, BRCA2, BRIP1, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, ; or actionable mutations in the PTEN gene, or hotspot mutations in the PIK3CA gene (E542, E545 or H1047 are accepted)?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Does patient have known SMARCB1- and SMARCA4-mutations?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Are there SPOP mutations in prostate cancer cells, as indicated by Next Generation Sequencing (NGS)?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"If patient has actionable mutations, treatment with Durvalumab during consolidative phase will be at physician discretion?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EC09928-DD48-2B1A-E053-F662850A1238","latestVersionIndicator":"Yes","beginDate":"2016-10-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-13","modifiedBy":"SOKKERL","dateModified":"2024-02-23","changeDescription":"10/19/16 tt, released. 10/13/16 tt, 9767. Fix special char in Ref Doc 03-24-2020 DW","administrativeNotes":"5/4/23:Add AQT LS","unresolvedIssues":null,"deletedIndicator":"No"}}